Cultivates cannabis in environmentally friendly greenhouses. Manufactures pharmaceutical-grade cannabis extracts. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 49% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 49% a year on average.
Sales run at $268.8M a year. A small number, but proof the product has real buyers.
There is $103.3T in the vault; even if every debt were paid off, $77.1T would remain.
A loss of $53.3M against $268.8M in annual sales.
The stock sits at $0.45. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.